Literature DB >> 2999616

The affinity of (-)-propranolol for beta 1- and beta 2-adrenoceptors of human heart. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline.

E Gille, H Lemoine, B Ehle, A J Kaumann.   

Abstract

An appraisal of the affinity of (-)-propranolol was made for beta-adrenoceptors of isolated heart preparations and myocardial membrane particles from patients undergoing open heart surgery. In order to eliminate possible distorting influences of neuronal and extraneuronal uptakes of catecholamines on the affinity estimates for (-)-propranolol, isolated tissues were pretreated once with 5 or 10 mumol/l phenoxybenzamine for 2 h. Phenoxybenzamine caused potentiation of the positive inotropic effects of (-)-noradrenaline and (-)-adrenaline but not of (-)-isoprenaline; potentiation was more pronounced in atrial than in ventricular preparations. Potentiation was greater for (-)-noradrenaline than for (-)-adrenaline. It is concluded that the concentration of physiological catecholamines at the human heart beta-adrenoceptors is limited by neuronal capture but not by extraneuronal uptake. The antagonism of the positive inotropic effects of (-)-adrenaline and (-)-noradrenaline by (-)-propranolol was simple competitive in left ventricular myocardium of patients with mitral lesion. The effects of (-)-adrenaline and (-)-noradrenaline were antagonized to similar extent by (-)-propranolol. An equilibrium dissociation constant KB (-log mol/l) of 8.6 was estimated for (-)-propranolol. In atrial preparations the inotropic effects of (-)-adrenaline were antagonized significantly more by (-)-propranolol than those of (-)-noradrenaline. KB-Values (-log mol/l) of 8.9 [against (-)-adrenaline] and 8.5 [against (-)-noradrenaline] were estimated for (-)-propranolol. Concentration-effect curves for the stimulation of adenylate cyclase of both atrium and ventricle were biphasic for (-)-noradrenaline and monophasic for (-)-adrenaline. The high-sensitivity and low-sensitivity components of (-)-noradrenaline comprised 1/3 and 2/3, respectively, of maximum cyclase stimulation. As expected from beta 1-adrenoceptors, the high-sensitivity component of the curve for (-)-noradrenaline was selectively antagonized by (-)-bisoprolol; as expected from beta 2-adrenoceptors, the low-sensitivity component was selectively antagonized by ICI 118,551. (-)-Propranolol antagonized the effects of (-)-noradrenaline mediated by beta 2-adrenoceptors 2 to 3 times more potently than the effects mediated by beta 1-adrenoceptors. (-)-Propranolol competed with 3H-(-)-bupranolol for binding to left ventricular beta-adrenoceptors. An equilibrium dissociation constant (-log mol/l) of 8.6 was estimated for (-)-propranolol.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2999616     DOI: 10.1007/bf00498852

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  38 in total

1.  Potentiation of the effects of isoprenaline and noradrenaline by hydrocortisone in cat heart muscle.

Authors:  A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

2.  The human heart beta-adrenergic receptors. II. Coupling of beta 2-adrenergic receptors with the adenylate cyclase system.

Authors:  M Waelbroeck; G Taton; M Delhaye; P Chatelain; J C Camus; R Pochet; J L Leclerc; J M De Smet; P Robberecht; J Christophe
Journal:  Mol Pharmacol       Date:  1983-09       Impact factor: 4.436

3.  Improved evaluation of binding of ligands to membranes containing several receptor-subtypes.

Authors:  B Ehle; H Lemoine; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

4.  Different steric characteristics of beta 1- and beta 2-adrenoceptors.

Authors:  T H Morris; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

5.  3H-(-)-Bupranolol, a new beta-adrenoceptor radioligand: characterization of its binding to kitten heart beta-adrenoceptors.

Authors:  T H Morris; K Sandrock; A J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-08       Impact factor: 3.000

6.  Direct labelling of myocardial beta 1-adrenoceptors. Comparison of binding affinity of 3H-(-)-bisoprolol with its blocking potency.

Authors:  A J Kaumann; H Lemoine
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

7.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

8.  Catecholamine uptake by isolated coronary arteries and atria of the kitten.

Authors:  E J Cornish; R G Goldie; R C Miller
Journal:  Br J Pharmacol       Date:  1978-07       Impact factor: 8.739

9.  Coexistence of beta 1- and beta 2-adrenoceptors in human right atrium. Direct identification by (+/-)-[125I]iodocyanopindolol binding.

Authors:  O E Brodde; K Karad; H R Zerkowski; N Rohm; J C Reidemeister
Journal:  Circ Res       Date:  1983-12       Impact factor: 17.367

10.  [Cardiac beta receptors--experimental aspects].

Authors:  A J Kaumann
Journal:  Z Kardiol       Date:  1983-02
View more
  68 in total

1.  Desensitization and resensitization of beta 1- and putative beta 4-adrenoceptor mediated responses occur in parallel in a rat model of cardiac failure.

Authors:  A R Kompa; R J Summers
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

2.  Putative beta 4-adrenoceptors in rat ventricle mediate increases in contractile force and cell Ca2+: comparison with atrial receptors and relationship to (-)-[3H]-CGP 12177 binding.

Authors:  D Sarsero; P Molenaar; A J Kaumann; N S Freestone
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

3.  Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.

Authors:  C Hoffmann; M R Leitz; S Oberdorf-Maass; M J Lohse; K-N Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-01-17       Impact factor: 3.000

4.  Human atrial β(1L)-adrenoceptor but not β₃-adrenoceptor activation increases force and Ca(2+) current at physiological temperature.

Authors:  Torsten Christ; Peter Molenaar; Paul M Klenowski; Ursula Ravens; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

5.  Characterization and autoradiographic localization of beta-adrenoceptor subtypes in human cardiac tissues.

Authors:  B F Buxton; C R Jones; P Molenaar; R J Summers
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

6.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

7.  Direct labelling of myocardial beta 1-adrenoceptors. Comparison of binding affinity of 3H-(-)-bisoprolol with its blocking potency.

Authors:  A J Kaumann; H Lemoine
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

8.  Phosphodiesterase PDE2 activity, increased by isoprenaline, does not reduce β-adrenoceptor-mediated chronotropic and inotropic effects in rat heart.

Authors:  Alejandro Galindo-Tovar; María Luisa Vargas; Alberto J Kaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-19       Impact factor: 3.000

Review 9.  Understanding How Phosphorylation and Redox Modifications Regulate Cardiac Ryanodine Receptor Type 2 Activity to Produce an Arrhythmogenic Phenotype in Advanced Heart Failure.

Authors:  Alexander Dashwood; Elizabeth Cheesman; Nicole Beard; Haris Haqqani; Yee Weng Wong; Peter Molenaar
Journal:  ACS Pharmacol Transl Sci       Date:  2020-06-01

10.  Beta 1- and beta 2-adrenoceptor-mediated relaxation in human internal mammary artery and saphenous vein: unchanged beta- and alpha-adrenoceptor responsiveness after chronic beta 1-adrenoceptor blockade.

Authors:  A Ferro; A J Kaumann; M J Brown
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.